EUVIMEDEUVIMED entdecken
Crossref

Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience

Derya Koyun, Güldane Cengiz Seval, Metin Sökmen, Erman Akkuş, Erden Atilla, Sinem Civriz Bozdağ, Pervin Topçuoğlu, Önder Arslan, Taner Demirer, Günhan Gürman, Osman İlhan, Meral Beksaç und 1 weitere

LLM Dergi · 2021

DOI: 10.5578/llm.20219802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LLM Dergi, 2021. Verfasst von Derya Koyun und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Koyun, D., Seval, G. C., Sökmen, M., Akkuş, E., Atilla, E., Bozdağ, S. C., Topçuoğlu, P., Arslan, Ö., Demirer, T., Gürman, G., İlhan, O., Beksaç, M., & Toprak, S. K. (2021). Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience. LLM Dergi. https://doi.org/10.5578/llm.20219802

Vancouver

Koyun D, Seval GC, Sökmen M, Akkuş E, Atilla E, Bozdağ SC, et al. Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience. LLM Dergi. 2021. doi:10.5578/llm.20219802

BibTeX
@article{Koyun2021,
  author = {Koyun, Derya and Seval, Güldane Cengiz and Sökmen, Metin and Akkuş, Erman and Atilla, Erden and Bozdağ, Sinem Civriz and Topçuoğlu, Pervin and Arslan, Önder and Demirer, Taner and Gürman, Günhan and İlhan, Osman and Beksaç, Meral and Toprak, Selami Koçak},
  title = {Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience},
  journal = {LLM Dergi},
  year = {2021},
  doi = {10.5578/llm.20219802}
}
Kostenlos starten →